Effect of sodium ozagrel on the activity of rat CYP2D6

被引:5
|
作者
Wu, Hong
Yu, Weijiang
Huang, Lijun
Wang, Jing
Tang, Xiaobo
Yang, Wei
Liu, Yan
Yu, Huiyan
Zhu, Daling
机构
[1] Harbin Med Univ, Coll Pharm, Harbin 150081, Heilongjiang, Peoples R China
[2] Biopharmaceut Key Lab Heilongjiang Prov, Harbin 150081, Peoples R China
[3] Mudanjiang Med Coll, Mudanjiang 157011, Peoples R China
关键词
ozagrel-1; CYP2D6; microsorne; HPLC; dextromethorphan;
D O I
10.1016/j.ejphar.2007.06.055
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to investigate the influence of sodium ozagrel on CYP2D6 (cytochromeP450 2D6) activity. The studies were performed with rat urine and liver microsomes and chemical inhibitors. The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC). The results showed that the metabolism of dextrophan/dextromethorphan in the sodium ozagrel-treated group (37 mg/kg) was higher than that of the control (P < 0.05/6) in both in vivo and in vitro studies (r=0.9811). The rate of dextromethorphan metabolism was inhibited by sodium ozagrel and cimetidine in rat liver microsomes prepared from sodium ozagrel-treated rats and control rats group (sodium ozagrel IC50=26.5 mu M, cimetidine IC50=86.3 mu M in sodium ozagrel-treated group; sodium ozagrel IC50=13.9 mu M, cimetidine IC50=24.8 mu M in control group). The inhibitory effect of sodium ozagrel on CYP2D6 activity was noncompetitive with dextromethorphan with a K-i of 324.94 mu M. Kinetic parameters of the reactions were established by using Lineweaver-Burk with K-m=0.67 mM and V-max = 2.13 pm/min/mg protein for the sodium ozagrel-treated group and K-m=0.29 mM, and V-max =0.91 pm/min/mg protein for the control group, respectively. The expression of CYP2D6 protein in the treated group was higher than that of the control group, as determined by Western blotting. The activity and expression of CYP1A2 did not show obvious differences in the control group and sodium ozagrel treated group. In conclusion, sodium ozagrel metabolism in rats is mediated primarily through CYP2D6, and sodium ozagrel can induce CYP2D6 activity. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [31] Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients
    Solai, LK
    Pollock, BG
    Mulsant, BH
    Frye, RF
    Miller, MD
    Sweet, RA
    Kirshner, M
    Sorisio, D
    Begley, A
    Reynolds, CF
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (05) : 481 - 486
  • [32] Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population
    Cai, W. M.
    Chen, B.
    Zhang, W. X.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (01) : 95 - 98
  • [33] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [34] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [35] The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva
    Jin, Ye
    Zhang, Shuquan
    Hu, Pei
    Zheng, Xin
    Guan, Xiaoduo
    Chen, Rui
    Zhang, Shuyang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
  • [37] The hypoalgesic effect of tramadol in relation to CYP2D6
    Poulsen, L
    ArendtNielsen, L
    Brosen, K
    Sindrup, SH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) : 636 - 644
  • [38] The Effect of Cholesterol Depletion on the Localization of CYP2D6
    Fuchs, Robert
    Reed, Robert
    Backes, Wayne L.
    FASEB JOURNAL, 2019, 33
  • [39] Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes:: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity
    Ishiguro, A
    Kubota, T
    Ishikawa, H
    Iga, T
    CLINICA CHIMICA ACTA, 2004, 344 (1-2) : 201 - 204
  • [40] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124